Filing Details
20/20 Biolabs, Inc. (NASDAQ:AIDX) filed a Form 8-K with the Securities and Exchange Commission on July 01, 2026, disclosing a material event.
8k filedNASDAQ:AIDX
20/20 Biolabs, Inc. (AIDX) Reports Material Event to SEC
Filing Details 20/20 Biolabs, Inc. (NASDAQ:AIDX) filed a Form 8-K with the Securities and Exchange Commission on July 01, 2026, disclosing a material event. Market Context 20/20…
Market Context
20/20 Biolabs, Inc.'s stock currently trades at $0.61 with a market capitalization of $18.8M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for 20/20 Biolabs, Inc.'s stock.
All SEC filings for 20/20 Biolabs, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View AIDX Stock Page
Frequently Asked Questions
Where can I read AIDX's SEC filings?
Browse all filings on our AIDX SEC filings page.
What types of SEC filings does 20/20 Biolabs, Inc. file?
Public companies like 20/20 Biolabs, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.